Prevention of bone loss in renal transplant recipients: A prospective, randomized trial of intravenous pamidronate

Journal of the American Society of Nephrology

Volumn 14, Issue 10, 2003, Pages 2669-2676

  Coco, Maria ^a,c   Glicklich, Daniel ^a   Faugere, Marie Claude ^b   Burris, Larry ^a   Bognar, Istvan ^a   Durkin, Peter ^a   Tellis, Vivian ^a   Greenstein, Stuart ^a   Schechner, Richard ^a   Figueroa, Katherine ^a   McDonough, Patricia ^a   Wang, Guodong ^b   Malluche, Hartmut ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CALCIUM; CALCIUM CARBONATE; PAMIDRONIC ACID; VITAMIN D;

ADULT; ARTICLE; BONE BIOPSY; BONE DENSITY; BONE MASS; BONE MINERAL; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENSITOMETRY; DISEASE ASSOCIATION; FEMALE; FRACTURE; HUMAN; HYPOPHOSPHATEMIA; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; MORPHOMETRICS; OSTEOLYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RENAL OSTEODYSTROPHY; VERTEBRA;

EID: 10744232811     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000087092.53894.80     Document Type: Article

References (39)

1. Malluche H, Faugere MC: Renal bone disease in 1990: An unmet challenge for the nephrologists. Kidney Int 38: 193-211, 1990
2. Sherrard D, Hercz G, Pei Y, Maloney NA, Greenwood C, Manuel A, Saiphoo C, Fenton SS, Segre GV: The spectrum of bone disease in end-stage renal failure: An evolving disorder. Kidney Int 43: 436-442, 1993
3. Ziegler R, Kasperk C: Glucocorticoid-induced osteoporosis: Prevention and treatment. Steroids 63: 344-348, 1998
4. Faugere MC, Mawad H, Qi Q, Friedler R, Malluche H: High prevalence of low bone turnover and occurrence of osteomalacia after kidney transplantation. J Am Soc Nephrol 11: 1093-1099, 2000
5. Lane N, Lukert B: The science and therapy of glucocorticoids-induced bone loss. Endocrinol Metab Clin North Am 27: 465-483, 1998
6. Eastell R, Reid DM, Compston J, Cooper C, Fogelman R, Francis RM, Hosking DJ, Purdie DW, Ralston SH, Reeve J, Russell R, Stevenson JC, Torgerson DJ: A UK Consensus Group on management of glucocorticoids induces osteoporosis: An update. J Intern Med 224: 271-292, 1998
7. Movsowitz C, Schlosberg M, Epstein S, Ismail F, Fallon M, Thomas S: Combined treatment with cyclosporine A and cortisone acetate minimizes the adverse bone effects of either agent alone. J Orthop Res 635: 641, 1990
8. Wolpaw T, Deal C, Fleming-Brooks S, Bartucci M, Schulak J, Hricik D: Factors influencing vertebral bone density after renal transplantation. Transplantation 58: 1186-1189, 1994
9. Julian B, Laskow D, Dubovsky J, Dubovsky EV, Curtis J, Quarles LD: Rapid loss of vertebral bone mineral density after renal transplantation. N Engl J Med 325: 544-550, 1991
10. Chiu M, Sprague S, Bruce D, Woodle E, Thistlewaite J, Josephson M: Analysis of fracture prevalence in kidney pancreas allograft recipients. J Am Soc Nephrol 677: 683, 1998
11. Adachi JD, Benson W, Brown J, Hanley D, Hodsman A, Josse R, Kendler D, Lentle B, Olszynski W, Ste-Marie L, Tenenhouse A, Chines A: Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 337: 382-387, 1997
12. Saag KG, Emkey R, Schnitzer T, Brown J, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG: Alendronate for the prevention and treatment of glucocorticoid induced osteoporosis. N Engl J Med 339: 292-299, 1998
13. Garcia-Delgado I, Prieto S, Gil-Fraguas L, Robles E, Rufilanchas J, Hawkins F: Calcitonin, etidronate, and calcidiol treatment in bone loss after cardiac transplantation. Calcif Tissue Int 60: 155-159, 1997
14. Bianda T, Linka A, Junga G, Brunner H, Steinhart H, Kiowski W, Schmid C: Prevention of osteoporosis in heart transplant recipients: A comparison of calcitriol with calcitonin and pamidronate. Calcif Tissue Int 67: 116-121, 2000
15. Bishop NJ, Ninkovic M, Alexander G, Holmes S, Milligan T, Price C, Compston J: Changes in calcium homoeostasis in patients undergoing liver transplantation: Effects of a single infusion of pamidronate administered pre-operatively. Clin Sci 97: 157-163, 1999
16. Riemens SC, Oostdijk A, van Doormaal J, Thijn C, Drent G, Piers D, Goen E, Meerman L, Sloof M, Haagsma E: Bone loss after liver transplantation is not prevented by cyclical etidronate, calcium and alphacalcidol. Osteoporos Int 6: 213-218, 1996
17. Valero MA, Loinaz C, Larrodera L, Leon M, Moreno E, Hawkins F: Calcitonin and bisphosphonates treatment in bone loss after liver transplantation. Calcif Tissue Int 57: 15-19, 1995
18. Grotz WH, Rump LC, Niessen A, Schmidt-Gayk H, Reichelt A, Kirste G, Olschewski M, Schollmeyer PJ: Treatment of osteopenia and osteoporosis after kidney transplantation. Transplantation 66: 1004-1008, 1998
19. Fan S, Almond M, Ball E, Evans K, Cunningham J: Pamidronate therapy as prevention of bone loss following renal transplantation. Kidney Int 57: 684-690, 2000
20. Briner V, Thiel G, Monier-Faugere MC, Bognar B, Landmann J, Kamber V, Malluche H: Prevention of cancellous bone loss but persistence of renal bone disease despite normal 1,25 Vitamin D levels two years after kidney transplantation. Transplantation 59: 1393-1400, 1995
21. Weber T, Quarles LD: Preventing bone loss after renal transplantation with bisphosphonates: We can ... but should we? Kidney Int 57: 735-737, 2000
22. Malluche HH, Faugere MC: Atlas of Mineralized Bone Histology, New York, Karger, 1986
23. Goldner J: A modification of the Masson trichrome technique for routine laboratory purposes. Am J Pathol 14: 237, 1938
24. Lillie RD, Donaldson P, Jirge SK, Pizzolato P: Iron and aluminum lakes of Gallo blue E as nuclear and metachromatic stains. Stain Technol 51: 187-192, 1976
25. Denton J, Freemont AJ, Ball J: Detection and distribution of aluminium in bone. J Clin Pathol 37: 136-42, 1984
26. Malluche HH, Sherman D, Meyer W, Massry SG: A new semi-automatic method for quantitative static and bone histology. Calcif Tissue Int 34: 439-438, 1982
27. Manaka RC, Malluche HH: A program package for quantitative analysis of histologic structure and remodeling dynamics of bone. Comput Programs Biomed 12: 191-210, 1981
28. Parfitt AM, Dresner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR: Bone histomorphometry: Standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2: 595-610, 1987
29. Haas M, Leko-Mohr Z, Roschger P, Kletzmayr J, Schwarz C, Mitterbauer C, Steininger R, Grampp S, Klaushofer K, Delling G, Oberbauer R: Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation. Kidney Int 63: 1130-1136, 2003
30. Rojas E, Carlini R, Clesca P, Arminio A, Suniaga O, Elguezabal K, Weisinger J, Hruska K, Bellorin-Front E: The pathogenesis of osteodystrophy after renal transplantation as detected by early alterations in bone remodeling. Kidney Int 63: 1915-1923, 2003
31. Fleisch H: Bisphosphonates: Mechanisms of action. Endocr Rev 19: 80, 1998
32. Christenson R: Biochemical markers of bone metabolism: An overview. Clin Biochem 30: 573-593, 1997
33. Finkelstein JS, Klibanski A, Schaefer EH, Hornsten MD, Schiff I, Neer RM: Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. N Engl J Med 331: 1618-1623, 1994
34. Neer R, Arnaud C, Zanchetti J, Prince R, Gaich G, Reginster J, Hodsman A, Eriksen E, Sharlom S, Genant H, Wang O, Mitlak B, Mellstrom D, Oefiord E, Suchowierska E, Salmi J, Mulder H, Halse J, Sawick A: Effect of parathyroid hormone (1-34) on fractures and BMD in post-menopausal women with osteoporosis. N Engl J Med 344: 1434-1441, 2001
35. Lips P: Epidemiology and predictors of fractures associated with osteoporosis. Am J Med 103: 3S-8S, 1997
36. Ross PD: Risk factors for osteoporotic fracture. Endocrinol Metab Clin North Am 27: 289-301, 1998
37. Grotz W, Nagel C, Poeschel D, Cybulla M, Petersen K, Uhl M, Strey C, Kirste G, Olschewski M, Reichelt A, Rump L: Effect of ibandronate on bone loss and renal function after kidney transplantation. J Am Soc Nephrol 12: 1530-1537, 2001
38. Atsumi K, Kushida K, Yamazaki K, Shimizu S, Ohmura A, Inoue T: Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis 33: 287-293, 1999
39. Coco M, Rush H: Increased incidence of hip in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 36: 1115-1121, 2000